As of now, Spironolactone is not approved by the European Medicines Agency (EMA) for weight loss, and it remains in various stages of clinical investigation for this specific indication
Smaller portions are a big factor as well
Beyond alcohol use disorder, the medications also reduced the risk of hospitalization for any substance use disorder and physical illnesses
Unlike diets that depend on ongoing behavioral effort and restrict food intake, tirzepatide reduces the motivation to overeat by resetting hunger signals to normal levels
And seeing that compounded medication has served a key role in filling the gap for estimated millions of patients affected by the Mounjaro and Zepbound shortages, dating back to December 2022, will there be adequate supply to continue to care for all of these patients as well
Brian Alman, PhD This is so cool Sean